Olaparib in Patients With HRD Malignant Mesothelioma
Status:
Recruiting
Trial end date:
2025-10-15
Target enrollment:
Participant gender:
Summary
In this study, researchers will give olaparib (a drug) to mesothelioma patients who have
specific changes in their DNA (known as gene mutations). Researchers will give this drug to
each patient on the study to find out if it will help the patient's tumor shrink or stop
growing.